Literature DB >> 1682830

Deterioration rate in hypertensive IgA nephropathy: comparison of a converting enzyme inhibitor and beta-blocking agents.

S Rekola1, A Bergstrand, H Bucht.   

Abstract

The effect of beta-blocking agents and enalapril as antihypertensive drugs has been compared in 47 patients with IgA nephropathy. The deterioration rate was calculated from the regression line of 51Cr-EDTA clearance and expressed in ml/min/year. The annual loss in glomerular filtration rate (GFR) was greater in patients treated with different beta-blocking agents (-4.9 +/- 6.8 ml/min/year) compared to patients treated with Enalapril (1.7 +/- 7.4 ml/min/year), in spite of the fact that these patients had a lower initial GFR. Nine patients were initially treated with beta-blocking agents (-9.5 +/- 9.3 ml/min/year) and then with an angiotensin-converting enzyme inhibitor (5.5 +/- 11.2 ml/min/year). Angiotensin-converting enzyme inhibitors should therefore be preferred in the treatment of hypertension in IgA nephropathy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1682830     DOI: 10.1159/000186518

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  10 in total

1.  Association of angiotensinogen gene T235 variant with progression of immunoglobin A nephropathy in Caucasian patients.

Authors:  Y Pei; J Scholey; K Thai; M Suzuki; D Cattran
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

Review 2.  Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy?

Authors:  F M Rasche; F Keller; W G Rasche; S Schiekofer; A Boldt; U Sack; J Fahnert
Journal:  Clin Exp Immunol       Date:  2016-09-08       Impact factor: 4.330

3.  Sequential therapy with cyclophosphamide and mycophenolic acid in patients with progressive immunoglobulin A nephropathy: a long-term follow-up.

Authors:  F M Rasche; F Keller; W G Rasche; S Schiekofer; T Kahn; J Fahnert
Journal:  Clin Exp Immunol       Date:  2015-11-26       Impact factor: 4.330

Review 4.  Renal protection and antihypertensive drugs: current status.

Authors:  A Salvetti; P Mattei; I Sudano
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

5.  Significance of the duration of nephropathy for achieving clinical remission in patients with IgA nephropathy treated by tonsillectomy and steroid pulse therapy.

Authors:  Norio Ieiri; Osamu Hotta; Toshinobu Sato; Yoshio Taguma
Journal:  Clin Exp Nephrol       Date:  2011-09-13       Impact factor: 2.801

6.  Role of the deletion of polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy.

Authors:  H Yoshida; T Mitarai; T Kawamura; T Kitajima; Y Miyazaki; R Nagasawa; Y Kawaguchi; H Kubo; I Ichikawa; O Sakai
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

Review 7.  Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension.

Authors:  P A Todd; K L Goa
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

8.  Clinical course of patients with IgA nephropathy between combined treatment of immunosuppressive agents and ACE inhibitor and ACE inhibitor alone.

Authors:  Y C Hwang; T W Lee; M J Kim; M H Yang; C G Ihm
Journal:  Korean J Intern Med       Date:  2001-06       Impact factor: 2.884

9.  ACE gene polymorphism and renal responsiveness to ACE inhibitors in IgA nephropathy patients.

Authors:  S Y Han; Y J Kwon; S K Jo; J H Shin; D R Cha; W Y Cho; H J Pyo; H K Kim
Journal:  Korean J Intern Med       Date:  2000-01       Impact factor: 2.884

10.  Decreased expression of transforming growth factor-β1 and α-smooth muscle actin contributes to the protection of lotensin against chronic renal failure in rats.

Authors:  Qingfei Xiao; Yinghui Guan; Chenhao Li; Li Liu; Dan Zhao; Hongyue Wang
Journal:  Ren Fail       Date:  2018-11       Impact factor: 2.606

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.